Antidote Treatment Nerve Agent Auto-Injector (ATNAA)

Agency: DEPT OF DEFENSE
State: Federal
Level of Government: Federal
Category:
  • 65 - Medical, Dental, and Veterinary Equipment and Supplies
Opps ID: NBD00159634861696207
Posted Date: Jun 6, 2023
Due Date:
Solicitation No: SPE2DP-23-R-0002
Source: Members Only
Follow
Antidote Treatment Nerve Agent Auto-Injector (ATNAA)
Active
Contract Opportunity
Notice ID
SPE2DP-23-R-0002
Related Notice
Department/Ind. Agency
DEPT OF DEFENSE
Sub-tier
DEFENSE LOGISTICS AGENCY (DLA)
Major Command
TROOP SUPPORT MEDICAL
Office
DLA TROOP SUPPORT
Looking for contract opportunity help?

Procurement Technical Assistance Centers (PTACs) are an official government contracting resource for small businesses. Find your local PTAC (opens in new window) for free government expertise related to contract opportunities.

General Information
  • Contract Opportunity Type: Sources Sought (Original)
  • All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
  • Original Published Date: Jun 06, 2023 03:21 pm EDT
  • Original Response Date:
  • Inactive Policy: Manual
  • Original Inactive Date: Jul 05, 2023
  • Initiative:
    • None
Classification
  • Original Set Aside:
  • Product Service Code:
  • NAICS Code:
  • Place of Performance:
Description

The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agent Auto-Injector (ATNAA). DLA Troop Support is contemplating awarding a one-year base and two one-year option, indefinite quantity contract for ATNAA. The quantities to be ordered are estimated at 225,000 units minimum and 1,000,000 units maximum per contract year. However, the quantity may increase or decrease as the Services requirements change.



The ATNAA shall be licensed by the Food and Drug Administration (FDA). Each auto-injector shall deliver 2.1 mg of atropine and 600mg of pralidoxime chloride in separate chambers, and be suitable for intramuscular administration.



Must have FDA approval to sell the ATNAA before award of the contract.



If your firm currently manufactures or distributes the ATNAA, please provide information with respect to the following:





a) Place of manufacture

b) Estimated annual capacity

c) FDA registration

d) Product name and description including description of any special features

e) Current unit sale price

f) Estimated inventory level and storage requirements





*** NEW PRODUCTS UNDER DEVELOPMENT***





For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture the ATNAA or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.





Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.





This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement.



Your response to this RFI may be submitted electronically in pdf format and emailed to danielle.delaney@dla.mil. Responses must be submitted by July 5, 2023.


Attachments/Links
No attachments or links have been added to this opportunity.
Contact Information
Contracting Office Address
  • MEDICAL SUPPLY CHAIN PHARM FSA 700 ROBBINS AVENUE
  • PHILADELPHIA , PA 19111
  • USA
Primary Point of Contact
Secondary Point of Contact


History
  • Jun 06, 2023 03:21 pm EDTSources Sought (Original)

Related Document

Mar 20, 2024[Presolicitation (Original)] Antidote Treatment Nerve Agent Auto-Injector (ATNAA)
Apr 12, 2024[Presolicitation (Updated)] Antidote Treatment Nerve Agent Auto-Injector (ATNAA)

TRY FOR FREE

Not a USAOPPS Member Yet?

Get unlimited access to thousands of active local, state and federal government bids and awards in All 50 States.

Start Free Trial Today >